[go: up one dir, main page]

AR045691A1 - Derivados de heteroarilamida como receptores antagonistas p2x7 y sus usos - Google Patents

Derivados de heteroarilamida como receptores antagonistas p2x7 y sus usos

Info

Publication number
AR045691A1
AR045691A1 ARP040101893A ARP040101893A AR045691A1 AR 045691 A1 AR045691 A1 AR 045691A1 AR P040101893 A ARP040101893 A AR P040101893A AR P040101893 A ARP040101893 A AR P040101893A AR 045691 A1 AR045691 A1 AR 045691A1
Authority
AR
Argentina
Prior art keywords
halogen
hydroxyl
group
alkyl
substituted
Prior art date
Application number
ARP040101893A
Other languages
English (en)
Inventor
Paul Willis
Richard Evans
Toby Thompson
Barrie Martin
Christine Eyssade
Rhonan Ford
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38812906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR045691(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR045691A1 publication Critical patent/AR045691A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procesos para su preparación, composiciones farmacéuticas que los contienen y su utilización con fines terapéuticos. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1) o una sal, prodroga o solvato aceptable para uso farmacéutico del mismo, donde p es 0, 1 o 2 ; cada R1 independientemente representa halógeno o alquilo C1-6 opcionalmente substituido por al menos un substituyente seleccionado entre hidroxilo, halógeno y alcoxi C1-6; q es 0, 1 o 2 ; cada R4 independientemente representa halógeno o alquilo C1-6 opcionalmente substituido por al menos un substituyente seleccionado entre hidroxilo, halógeno y alcoxi C1-6; m es 0, 1, 2 o 3; X es -C(O)NH- o -NHC(O)-; n es 0, 1, 2 o 3; dentro de cada agrupamiento CR5R6, R5 y R6 cada uno independientemente representa hidrógeno, alquilo C1-6 o R5 y R6 junto con el átomo de carbono al cual ambos se encuentran unidos puede formar un anillo cicloalquilo de 3 a 6 miembros; R2 representa un sistema de anillos cicloalquilo de 4 a 9 miembros, cuyo sistema de anillos cicloalquilo se puede substituir opcionalmente por al menos un substituyente independientemente seleccionado entre halógeno, hidroxilo, -S(O)falquilo C1-6, -NR7R8, -C(O)OR12, -OC(O)R13, -C(O)NR14R15, -SO2NR16R17, -NR18SO2R19, alcoxi C1-6, hidroxialquilo C1-6 o un grupo alquilo C1-6 cuyo grupo alquilo C1-6 puede ser opcionalmente substituido por al menos un halógeno; f es 0,1 o 2; uno de Y o Z es nitrógeno y el otro es un grupo CR3 donde R3 es un grupo de fórmula (2) donde X1 representa un átomo de oxígeno o azufre, o un grupo >N-R11 donde R11 es hidrógeno o un grupo alquilo C1-5 el cual puede substituirse opcionalmente por uno o más substituyentes seleccionados entre hidroxilo, halógeno o alcoxi C1-6; s es 0 o 1; R9 representa una unión o un grupo alquileno C1-5, el cual puede substituirse opcionalmente por al menos un substituyente seleccionado entre hidroxilo, halógeno y alcoxi C1-6; R10 representa hidrógeno, hidroxilo, carboxilo, -C(O)OR20, -NR21R22, -C(O)NOH, o un grupo -WR23; o R10 representa un anillo carbocíclico o heterocíclico de 4 a 9 miembros, cualquiera de los cuales puede incluir grupos puente, cuyo grupo carbocíclico y heterocíclico puede substituirse opcionalmente por al menos un substituyente seleccionado entre halógeno, hidroxilo, =O, carboxilo, ciano, alquilo C1-6, hidroxialquilo C1-6, un grupo -W'R24, -C(O)NOH, -(CH2)tNR25R26, - (CH2),C(O)NR27R21, -(CH2)tR29, -(CH2)tNR30C(O)R31, -S(O)rR32, NR33SO2R14, NR35C(O)NR36S(O)rR37, -S(O)r(CH2)tNR38R39, -NR40S(O)rNR41R42, -S(O)r(CH2)tC(O)OR43, o -M(CH2)tC(O)OR44 donde M representa una unión, O, o un grupo >NR45; t es 0, 1, 2, 3, 4, 5 o 6 ; r es 0, 1 o 2; R21 y R22 se seleccionan independientemente entre hidrógeno, alquenilo C2-7, alquilcarbonilo C1-6, -SO2R46, -C(O)NHSO2R47, un anillo carbocíclico o heterocíclico de 3 a 8 miembros cuyo anillo carbocíclico o heterocíclico puede substituirse opcionalmente por al menos un substituyente seleccionado entre halógeno, hidroxilo y carboxilo, o R21 y R22 pueden representar independientemente un grupo alquilo C1-7 cuyo grupo alquilo C1-7 puede substituirse opcionalmente por al menos un substituyente seleccionado entre halógeno, carboxilo, hidroxilo, -NH (CH2)2-4OH, alcoxi C1-6, alquiltio C1-6, alcoxicarbonilo C1-6, -NR48R49, -C(O)NR50R51, -NR52C(O)R53, -NR54SO2R55 y -NR67C(O)NR68SO2R56; W y W' independientemente representan una unión, O, S(O)p, -NR57C(O)-, - C(O)NR58, -SO2NR59, -NR60SO2-, >NR61, alquileno C1-6, o un grupo -O(CH2)1-6-, -S(O)p(CH2)1-6-, -NR62(CH2)1-6-, -(CH2)1-3O(CH2)1-3-, -(CH2)1-3S(O)p(CH2)1-3, -(CH2)1-3NR61(CH2)1-3-, -(CH2)1-3NR64C(O)(CH2)0-3-, -(CH2)1-3C(O)NR65(CH2)0-3-, o - S(O)p(CH2)1-6NR66-; p es 0, 1 o 2; R23 y R24 independientemente representan un anillo carbocíclico o heterocíclico de 3a 10 miembros que comprende de 1 a 5 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno y azufre, cuyo anillo carbocíclico o heterocíclico puede substituirse opcionalmente por al menos un substituyente seleccionado entre hidroxilo, =O, =S, nitro, ciano, amino, halógeno, -SO2alquilo C1-6, aquilcarbonilo C1-6, alcoxicarbonilo C1-6, alquilamino C1-6, di- alquilamino C1-6, y un grupo alquilo C1-6 cuyo grupo alquilo C1-6 se puede substituir opcionalmente por al menos un substituyente seleccionado entre halógeno y hidroxilo; R7, R8, R12, R13, R14, R15, R16, R17, R18 y R19 cada uno independientemente representa un átomo de hidrógeno o un grupo alquilo C1-6 opcionalmente substituido por al menos un substituyente seleccionado entre hidroxilo, halógeno y alcoxi C1-6, o cualquiera de R7 y R8, R14 y R15, R16 y R17 junto con el átomo de nitrógeno al cual ambos se encuentran unidos puede formar un anillo heterocíclico saturado de 3 a 8 miembros; R20, R34, R37, R46, R47, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66 R67 y R68 cada uno independientemente representa hidrógeno o un grupo alquilo C1-6 el cual puede substituirse opcionalmente por al menos un substituyente seleccionado entre halógeno y hidroxilo; R25, R26, R27, R28, R30, R31, R32, R33, R35, R36, R38, R39, R40, R41, R42, R43, R44, R45, R48, R49, R50, R51, R52 y R53 cada uno independientemente representa un átomo de hidrógeno o un alquilo C1-6, hidroxialquilo C2-6 o un grupo cicloalquilo C3-8, o cualquiera de R25 y R26, R27 y R28, R38 y R39, R41 y R42, R48 y R49, R50 y R51 junto con el átomo de nitrógeno al cual ambos se encuentran unidos puede formar un anillo heterocíclico saturado de 3 a 8 miembros; y R29 es arilo.
ARP040101893A 2003-06-02 2004-06-02 Derivados de heteroarilamida como receptores antagonistas p2x7 y sus usos AR045691A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0312609.1A GB0312609D0 (en) 2003-06-02 2003-06-02 Novel compounds
SE0301700A SE0301700D0 (sv) 2003-06-02 2003-06-10 Novel compounds

Publications (1)

Publication Number Publication Date
AR045691A1 true AR045691A1 (es) 2005-11-09

Family

ID=38812906

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101893A AR045691A1 (es) 2003-06-02 2004-06-02 Derivados de heteroarilamida como receptores antagonistas p2x7 y sus usos

Country Status (25)

Country Link
US (2) US7408065B2 (es)
EP (1) EP1633717B1 (es)
JP (1) JP4682128B2 (es)
KR (1) KR101244971B1 (es)
CN (1) CN1832925B (es)
AR (1) AR045691A1 (es)
AT (1) ATE446953T1 (es)
AU (1) AU2004242626B2 (es)
BR (1) BRPI0410933A (es)
CA (1) CA2526884C (es)
CO (1) CO5700720A2 (es)
DE (1) DE602004023840D1 (es)
ES (1) ES2333721T3 (es)
GB (1) GB0312609D0 (es)
IS (1) IS8190A (es)
MX (1) MXPA05012883A (es)
NO (1) NO20060001L (es)
RU (1) RU2347778C2 (es)
SA (1) SA04250155B1 (es)
SE (1) SE0301700D0 (es)
TW (1) TW200508214A (es)
UA (1) UA83659C2 (es)
UY (1) UY28342A1 (es)
WO (1) WO2004106305A1 (es)
ZA (1) ZA200509706B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
US20070225318A1 (en) * 2004-09-20 2007-09-27 Biolipox Ab Pyrazole Compounds Useful In The Treatment Of Inflammation
RU2007129779A (ru) * 2005-01-06 2009-02-20 Астразенека Аб (Se) Новые соединения пиридина
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
JP2009501216A (ja) * 2005-07-13 2009-01-15 アストラゼネカ アクチボラグ 新規なピリジン類縁体
CA2617310A1 (en) * 2005-08-01 2007-02-08 Phenomix Corporation Methods of preparing hetercyclic boronic acids and derivatives thereof
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
JP2009513691A (ja) * 2005-10-31 2009-04-02 バイオリポックス エービー リポキシゲナーゼ阻害剤としてのトリアゾール化合物
EP1943225A1 (en) * 2005-11-01 2008-07-16 Biolipox AB Pyrazoles useful in the treatment of inflammation
US8007849B2 (en) * 2005-12-14 2011-08-30 International Flavors & Fragrances Inc. Unsaturated cyclic and acyclic carbamates exhibiting taste and flavor enhancement effect in flavor compositions
CA2645556C (en) * 2006-03-16 2016-05-24 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
US20090298825A1 (en) * 2006-03-16 2009-12-03 Kelly Michael G Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
BRPI0709596A2 (pt) * 2006-03-16 2011-07-19 Renovis Inc compostos bicicloeteroarila como moduladores de p2x7 e seus usos
TWI464148B (zh) * 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
US20080058309A1 (en) * 2006-07-27 2008-03-06 Astrazeneca Ab Novel Compounds 171
EP2076495B1 (en) * 2006-09-28 2010-08-18 F. Hoffmann-La Roche AG Quinoline derivatives with 5-ht-binding properties
EP2591675A1 (en) 2006-11-27 2013-05-15 H. Lundbeck A/S Heteroaryl amide derivatives
CN101541753B (zh) 2006-12-07 2012-06-13 弗·哈夫曼-拉罗切有限公司 作为5-ht(5a)受体拮抗剂的2-氨基喹啉类化合物
MX2009010059A (es) * 2007-03-22 2009-10-12 Astrazeneca Ab Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
WO2008124153A1 (en) * 2007-04-10 2008-10-16 H. Lundbeck A/S Heteroaryl amide analogues as p2x7 antagonists
US8106073B2 (en) * 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
MX2010009403A (es) 2008-03-07 2010-09-24 Hoffmann La Roche Derivados de 2-aminoquinolina.
ATE494926T1 (de) 2008-03-25 2011-01-15 Affectis Pharmaceuticals Ag Neuartige p2x7r-antagonisten und ihre verwendung
ES2376092T3 (es) * 2008-04-22 2012-03-08 Janssen Pharmaceutica, N.V. Antagonistas de p2x7 sustituidos con quinolina o isoquinolina.
WO2010118921A1 (en) 2009-04-14 2010-10-21 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CA2761639C (en) * 2009-05-29 2016-06-07 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
BR112012028850A2 (pt) 2010-05-14 2015-09-15 Affectis Pharmaceuticals Ag métodos para a preparação de antagonistas de p2x7r
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
US9221832B2 (en) 2011-07-22 2015-12-29 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
KR102033190B1 (ko) 2012-01-20 2019-10-16 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 헤테로시클릭 아미드 유도체
KR102232742B1 (ko) 2012-12-12 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
EP2935211B1 (en) 2012-12-18 2016-11-09 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as p2x7 receptor antagonists
CA2896790C (en) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
CN104918946B (zh) 2013-01-22 2017-03-29 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
US10053463B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節物質
AR100724A1 (es) * 2014-06-05 2016-10-26 Merck Patent Gmbh Derivados de quinolina y su uso en enfermedades neurodegenerativas
WO2016039983A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulating n-acyl-triazolopyrazines
EA034015B1 (ru) 2014-09-12 2019-12-19 Янссен Фармацевтика Нв Модуляторы р2х7
CN106084068B (zh) * 2016-06-16 2019-07-16 郑州大学第一附属医院 一组肠菌素-抗生素衍生物及其应用
FI3609868T3 (fi) * 2017-03-13 2023-11-22 Raqualia Pharma Inc Tetrahydrokinoliinijohdannaisia P2X7-reseptorin antagonisteina
EP3398941A1 (en) * 2017-05-03 2018-11-07 AXXAM S.p.A. Heterocyclic p2x7 antagonists
MX2021003661A (es) 2018-09-28 2021-08-19 Janssen Pharmaceutica Nv Moduladores de la monoacilglicerol lipasa.
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
EP4038070B1 (en) 2019-09-30 2025-07-09 Janssen Pharmaceutica NV Radiolabelled mgl pet ligands
CA3176946A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
CN115305282A (zh) * 2022-08-04 2022-11-08 烟台毓璜顶医院 一种用于AR-induced OD诊断和预后判别的靶点及治疗方法
WO2025180517A1 (zh) * 2024-03-01 2025-09-04 武汉人福创新药物研发中心有限公司 含sf5类喹啉衍生物及其作为p2x7拮抗剂的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
US3741491A (en) * 1971-11-29 1973-06-26 Leesona Corp Apparatus for winding yarn
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
ATE148098T1 (de) 1991-02-21 1997-02-15 Sankyo Co Benzolderivate zum fördern der produktion des nervenwachstumsfaktors
EP0720601B1 (en) 1993-08-10 2000-10-25 James Black Foundation Limited Gastrin and cck receptor ligands
ES2227769T3 (es) 1994-05-27 2005-04-01 Glaxosmithkline S.P.A. Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina.
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
JP2000510865A (ja) * 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンカルボキサミド
FR2761358B1 (fr) 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2001524468A (ja) 1997-11-21 2001-12-04 エヌピーエス ファーマシューティカルズ インコーポレーテッド 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
HUP0202214A3 (en) 1999-04-09 2002-12-28 Astrazeneca Ab Adamantane derivatives, preparation and use thereof
HK1048635A1 (zh) 1999-06-02 2003-04-11 Nps药物有限公司 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
CA2389681C (en) * 1999-11-26 2010-11-02 Shionogi & Co., Ltd. Npy y5 antagonist
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
HRP20031080A2 (en) * 2001-07-02 2004-04-30 Akzo Nobel Nv Tetrahydroquinoline derivatives
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (sv) 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0402925D0 (sv) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds

Also Published As

Publication number Publication date
DE602004023840D1 (de) 2009-12-10
AU2004242626B2 (en) 2008-03-13
UY28342A1 (es) 2004-12-31
GB0312609D0 (en) 2003-07-09
SE0301700D0 (sv) 2003-06-10
CA2526884A1 (en) 2004-12-09
BRPI0410933A (pt) 2006-06-27
HK1085736A1 (en) 2006-09-01
US20060293337A1 (en) 2006-12-28
CO5700720A2 (es) 2006-11-30
EP1633717B1 (en) 2009-10-28
CA2526884C (en) 2012-10-16
TW200508214A (en) 2005-03-01
KR101244971B1 (ko) 2013-03-18
US7408065B2 (en) 2008-08-05
CN1832925A (zh) 2006-09-13
ZA200509706B (en) 2006-12-27
RU2005136130A (ru) 2006-06-27
US20090143354A1 (en) 2009-06-04
ATE446953T1 (de) 2009-11-15
IS8190A (is) 2005-12-21
ES2333721T3 (es) 2010-02-26
EP1633717A1 (en) 2006-03-15
SA04250155B1 (ar) 2008-11-15
CN1832925B (zh) 2010-05-05
JP4682128B2 (ja) 2011-05-11
MXPA05012883A (es) 2006-02-22
AU2004242626A1 (en) 2004-12-09
JP2006526617A (ja) 2006-11-24
NO20060001L (no) 2006-03-02
RU2347778C2 (ru) 2009-02-27
UA83659C2 (ru) 2008-08-11
KR20060015741A (ko) 2006-02-20
WO2004106305A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
AR045691A1 (es) Derivados de heteroarilamida como receptores antagonistas p2x7 y sus usos
AR030432A1 (es) Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica.
AR037736A1 (es) Derivados de pirimidina como moduladores o inhibidores de la actividad del factor de crecimiento insulinico tipo 1 (igf-1r)
AR037881A1 (es) Uso de derivados de oxindol
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR059458A1 (es) Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos
AR040498A1 (es) Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias
AR029469A1 (es) Compuesto de azaindol, compuesto de azaindol de utilidad como intermediario para preparar el anterior, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima
AR069692A1 (es) Peptidilnitrilos y sus usos como inhibidores de la dipeptidil peptidasa
AR039567A1 (es) Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa, composicion farmaceutica y procedimiento de preparacion del compuesto
AR035069A1 (es) Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento
AR035162A1 (es) Compuesto derivado de triazo-benzo-azulenona, composicion farmaceutica que lo comprende y su uso en la fabricacion de un agente util para inhibir la actividad parp de una enzima
AR038240A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
AR035714A1 (es) Pirazoles sustituidos y composiciones farmaceuticas que los contienen
AR034390A1 (es) Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa
AR037534A1 (es) Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios
AR036586A1 (es) Nuevas dihidro-pteridinonas, procedimientos para su preparacion, su utilizacion como medicamentos y las formulaciones farmaceuticas que las contienen
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR036604A1 (es) Derivados de 4-pirimidona 3-sustituida
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
NO20060974L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
AR045761A1 (es) Derivados de 2-piridona como inhibidores de elastasa de neutrofilos
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
AR018330A1 (es) Composiciones farmaceuticas que comprenden macrolidos como agentes activos para la terapia y profilaxis de las enfermedades de la piel
AR043875A1 (es) Derivados de quinazolina, proceso para su preparacion y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure